anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a biological information processor capable of reducing labor and time for inputting biological information, and to provide a biological information processing method.  <P>SOLUTION: In one embodiment, a display processing part 104 displays, at the screen of a display device, a graph where the measurement time and measurement value of vital data are respectively made to be X, Y axes. A data processing part 106 determines the measurement time and the measurement value respectively corresponding to the X, Y components of a designation coordinate by a designation operation for designating the coordinate of the display graph with the use of a mouse. In another embodiment, an operation processing part 112 selects one of the measurement times in the trend of the measurement values of the vital data. A server data communication part 110 acquires from a server system the plurality of measurement values at the plurality of measurement times during a period including the selected measurement time. A display processing part 104 displays the acquired measurement values at the screen of the display device. The operation processing part 112 selects one of the displayed measurement values. A data processing part 106 changes the measurement value in the trend at the selected measurement time into the selected measurement value.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Based on findings in animals and its mechanism of action, PIQRAY can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of alpelisib to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes, including embryo-fetal mortality (post-implantation loss), reduced fetal weights, and increased incidences of fetal malformations at maternal exposures based on area under the curve (AUC) that were ≥ 0.8 times the exposure in humans at the recommended dose of 300 mg/day. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with PIQRAY and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use condoms and effective contraception during treatment with PIQRAY and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].

Refer to the Full Prescribing Information of fulvestrant for pregnancy and contraception information.
From their early genesis, tumour cells integrate with the surrounding normal cells to form an abnormal structure that is tightly integrated with the host organism via blood and lymphatic vessels and even neural associations. Using these connections, emerging cancers send a plethora of mediators that efficiently perturb the entire organism and induce changes in distant tissues. These perturbations serendipitously favour early metastatic establishment by promoting a more favourable tissue environment (niche) that supports the persistence of disseminated tumour cells within a foreign tissue. Because the establishment of early metastatic niches represents a key limiting step for metastasis, the creation of a more suitable pre-conditioned tissue strongly enhances metastatic success. In this Review, we provide an updated view of the mechanisms and mediators of primary tumours described so far that induce a pro-metastatic conditioning of distant organs, which favours early metastatic niche formation. We reflect on the nature of cancer-induced systemic conditioning, considering that non-cancer-dependent perturbations of tissue homeostasis are also able to trigger pro-metastatic conditioning. We argue that a more holistic view of the processes catalysing metastatic progression is needed to identify preventive or therapeutic opportunities.
282,434. Becker, H. Dec. 16, 1926, [Convention date]. Void [Published under Sect. 91 of the Acts]. Bacteria, preparations for administering. - A preparation for the prevention and treatment of tuberculosis, diabetes, &c. consists of a culture of a bacterium originating from the intestines of dogs or doves (" bacillus erodiens "), either alone or with a digestion enzyme, and made up into the form of pills, tablets, or capsules, coated with keratin so as to be liberated only in the lower part of the intestine. The culture may also be administered per anum, or, for animals, in the form of a potato culture mixed with the fodder. The pill mass or excipient employed may be powdered liquorice root, extract of liquorice, or lactose.
GROUP 2 will receive beta-hydroxy-beta-methylbutyrate (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas. The investigators will limit HMB dosing to 3g/day since this is the most widely studied dose.
OBJECTIVES: Head trauma is a common presenting complaint among children requiring urgent medical attention, accounting for more than 600,000 emergency department (ED) visits annually, 4% to 30% of which identify skull fractures among the patient's injuries. Previous literature shows that children with basilar skull fractures (BSFs) are usually admitted for observation. We studied whether children with an isolated BSF have complications precluding them from safe discharge home from the ED.
METHODS: We performed a retrospective review of ED patients aged 0 to 18 years given a simple BSF diagnosis (defined by nondisplaced fracture, with normal neurologic examination, Glasgow Coma Score of 15, no intracranial hemorrhage, no pneumocephalus) during a 10-year period to identify complications associated with their injury. Complications were defined as death, vascular injury, delayed intracranial hemorrhage, sinus thrombosis, or meningitis. We also considered hospital length of stay (LOS) longer than 24 hours or any return visit within 3 weeks of the original injury.
RESULTS: Of the 174 patients included in the analysis, there were no deaths, cases of meningitis, vascular injury, nor delayed bleeding events. Thirty (17.2%) patients required a hospital LOS longer than 24 hours and 9 (5.2%) returned to the hospital within 3 weeks of discharge. Of those with LOS longer than 24 hours, 22 (12.6%) patients needed subspecialty consultation or intravenous fluids, 3 (1.7%) had cerebrospinal fluid leak, and 2 (1.2%) had a concern for facial nerve abnormality. On the return visits, only 1 (0.6%) patient required readmission for intravenous fluids because of nausea and vomiting.
CONCLUSIONS: Our findings suggest that patients with uncomplicated BSFs can be safely discharged from the ED if the patient has reliable follow-up, is tolerating oral fluids, has no evidence of cerebrospinal fluid leak, and has been evaluated by appropriate subspecialists before discharge.
INTRODUCTION: Reduced doses of emicizumab improve the affordability among patients in developing countries. However, the relationship between variant dose selection and efficacy in the real world of China is still unclear.
AIM: This study aimed to investigate the efficacy and safety of emicizumab especially in those on reduced dose regimens in a real-world setting.
METHODS: We carried out a multicentre study from 28 hospitals between June 2019 and June 2023 in China and retrospectively analysed the characteristics including demographics, diagnosis, treatment, bleeding episodes, and surgical procedures.
RESULTS: In total, 127 patients with haemophilia A, including 42 with inhibitors, were followed for a median duration of 16.0 (IQR: 9.0-30.0) months. Median age at emicizumab initiation was 2.0 (IQR: 1.0-4.0) years. Median (IQR) consumption for loading and maintenance was 12.0 (8.0-12.0) and 4.2 (3.0-6.0) mg/kg/4 weeks, respectively. While on emicizumab, 67 (52.8%) patients had no bleeds, whereas 60 (47.2%) patients had any bleeds, including 26 with treated bleeds. Compared to previous treatments, patients on emicizumab had significantly decreased annualized bleeding rate, annualized joint bleeding rate, target joints and intracerebral haemorrhage. Different dosages had similar efficacy except the proportion of patients with treated spontaneous bleeds and target joints. Adverse events were reported in 12 (9.4%) patients. Postoperative excessive bleeding occurred following two of nine procedures.
CONCLUSION: This is the largest study describing patients with HA receiving emicizumab prophylaxis on variant dose regimens in China. We confirmed that nonstandard dose is efficacious and can be considered where full-dose emicizumab is ill affordable.
Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
Background and Objectives: Anaerobic bacteria like Fusobacterium can lead to severe and life-threatening infections. The inherent complexities in the isolation of these bacteria may result in diagnostic and therapeutic delays, thereby escalating both morbidity and mortality rates. We aimed to examine data from patients with infections due to Fusobacterium to gain insights into the epidemiology and clinical outcomes of patients with these infections. Methods and Results: We conducted a retrospective analysis of clinical data from a cohort of patients with cultures positive for Fusobacterium species at a tertiary care medical center in the United States. Between 2009 and 2015, we identified 96 patients with cultures positive for Fusobacterium. Patients could be categorized into three groups based on the site of primary infection. Patients with head and neck infections constituted 37% (n 36). Patients with infections of other soft tissue sites accounted for 38.5% (n 37). Patients with anaerobic bacteremia due to Fusobacterium formed 24% (n 23) of the cohort. Surgical intervention coupled with antibiotic therapy emerged as cornerstones of management for patients with head and neck or other soft tissue infections, who generally exhibited more favorable outcomes. Patients with bacteremia were older, more likely to have malignancy, and had a high mortality rate. When speciation was available, Fusobacterium necrophorum was the most frequently isolated species. Conclusions: Our retrospective analysis of epidemiology and clinical outcomes of Fusobacterium infections revealed three distinct cohorts. Patients with head, neck, or soft tissue infections had better outcomes than those with bacteremia. Our findings highlight the importance of employing management strategies based on infection site and underlying comorbidities in patients with Fusobacterium infections. Further research is needed to investigate the optimal therapeutic strategies and identify prognostic indicators to improve clinical outcomes for these complex infections.
INTRODUCTION: Silver nanoparticles (AgNPs) have been found to exhibit unique properties which show their potential to be used in various therapies. Green synthesis of AgNPs has been progressively gaining acceptance due to its cost-effectiveness and energy-efficient nature.
OBJECTIVE: In the current study, aqueous extract of Thymus vulgaris (T. vulgaris) was used to synthesize the AgNPs using green synthesis techniques followed by checking the effectiveness and various biological activities of these AgNPs.
METHODS: At first, the plant samples were proceeded for extraction of aqueous extracts followed by chromatography studies to measure the phenolics and flavonoids. The synthesis and characterization of AgNPs were done using green synthesis techniques and were confirmed using Fourier transform infra-red (FT-IR) spectroscopy, UV-visible spectroscopy, scanning electron microscope (SEM), zeta potential, zeta sizer and X-Ray diffraction (XRD) analysis. After confirmation of synthesized AgNPs, various biological activities were checked.
RESULTS: The chromatography analysis detected nine compounds accounting for 100% of the total amount of plant constituents. The FT-IR, UV-vis spectra, SEM, zeta potential, zeta sizer and XRD analysis confirmed the synthesis of AgNPs and the variety of chemical components present on the surface of synthesized AgNPs in the plant extract. The antioxidant activity of AgNPs showed 92% inhibition at the concentration of at 1000 µg/mL. A greater inhibitory effect in anti-diabetic analysis was observed with synthesized AgNPs as compared to the standard AgNPs. The hemolytic activity was low, but despite low concentrations of hemolysis activity, AgNPs proved not to be toxic or biocompatible. The anti-inflammatory activity of AgNPs was observed by in-vitro and in-vivo approaches in range at various concentrations, while maximum inhibition occurs at 1000 µg (77.31%).
CONCLUSION: Our data showed that the potential biological activities of the bioactive constituents of T. vulgaris can be enhanced through green synthesis of AgNPs from T. vulgaris aqueous extracts. In addition, the current study depicted that AgNPs have good potential to cure different ailments as biogenic nano-medicine.
The infantile diarrhea ointment belongs to a medical ointment prepared from Chinese herbal medicines. It solves the problem of external treatment of internal diseases such as diarrhea and dysmenorrhea. The main formula of the medicine is 12 Chinese herbal medicines of ginger, scallion, evodia rutaecarpa, cinnamon and the like. The preparation method comprises mixing the above materials, processing, grinding into fine powder, sieving with 120 mesh sieve, refining vegetable oil to predetermined value, adding Plumbum Preparatium, removing fire toxin, and mixing with the medicinal powder. It has effects in activating yang, dispelling cold, invigorating spleen, regulating intestine, and promoting digestion. It can be used for treating infantile diarrhea, dyspepsia, abdominal pain, dysmenorrhea, and ulcer of limbs.
Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
Individually titrate DILAUDID Oral Solution or DILAUDID Tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving DILAUDID Oral Solution or DILAUDID Tablets to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.2, 5.14)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the DILAUDID Oral Solution or DILAUDID Tablets dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

A supplemental dose of 5 to 15% of the total daily usage may be administered every two hours on an as-needed basis.
PROBLEM TO BE SOLVED: To obtain a carcinogenic preventing agent, comprising a glycoside derived from a plant body of a cruciferous plant, having antimutagenic actions and capable of manifesting chemical carcinogenic preventing effects on a rise in activities of a carcinogenic preventing enzyme group. SOLUTION: This carcinogenic preventing agent comprises a glycoside derived from a cruciferous plant body as an active ingredient and the characteristic thereof comprises antimutagenic actions of the glycoside. The glycoside is preferably obtained by extracting a plant body of the cruciferous plant such as a Japanese radish, a cabbage or a leaf mustard under inactivating or deactivating conditions for a myrosinase.  Concretely, a Japanese radish-derived glycosinolate which is the Japanese radish-derived glycoside is prepared by adding, e.g. a 20mM tris hydrochloric acid buffer solution at pH7.5 to the Japanese radish, pulverizing the Japanese radish, then centrifuging the pulverized mixture, subsequently dialyzing the resultant supernatant against a solution of hydrogen peroxide which is an inhibitor of the myrosinase, then vacuum concentrating the outer dialyzate, adsorbing the prepared concentrate on active carbon, further eluting the adsorbed substance with a 60% (vol./vol.) ethanol solution and successively carrying out the treatment with a water immersion type ODS and gel filtration of the eluted fraction.
There have not been any studies published which specifically describe the medical, environmental, and genetic factors in carcinoid tumors cases that have carcinoid in family members. While rare, with an incidence of four per 100, 000, carcinoid represents the most frequent malignancy affecting the small intestine. Because nearly half (49%) of the cases of gastrointestinal carcinoid tumors have hepatic metastasis at diagnosis, identification of the risk factors associated with carcinoid has the potential to increase early diagnosis and cure. Carcinoid tumors are thought to occur spontaneously and not associated with an inherited genetic abnormality that would increase a family member's risk for developing carcinoid cancer. There is a known inherited genetic abnormality that is associated with bronchial carcinoid tumors but only less than 10%. Gastrointestinal carcinoid tumors are not thought to be associated with a inherited genetic abnormality. There have been several small studies that have examined gastrointestinal carcinoid in multiple family members. It remains uncertain if these cases of carcinoid in multiple family members are characteristic of a heritable or environmental etiology. Most carcinoid cancer is not inherited; however, less than 10% of neuroendocrine carcinoid cancer is thought to be due to a change (called a "mutation") in a gene inherited from a parent. There are several genes that are suspected to be associated with carcinoid cancer, two of interest in this study is the Multiple Endocrine Neoplasia Type1 (MEN1), and succinate dehydrogenase complex, subunit D (SDHD) genes.
Sepsis is a systemic response to infection with life-threatening consequences. Our understanding of the molecular and cellular impact of sepsis across organs remains rudimentary. Here, we characterize the pathogenesis of sepsis by measuring dynamic changes in gene expression across organs. To pinpoint molecules controlling organ states in sepsis, we compare the effects of sepsis on organ gene expression to those of 6 singles and 15 pairs of recombinant cytokines. Strikingly, we find that the pairwise effects of tumor necrosis factor plus interleukin (IL)-18, interferon-gamma or IL-1β suffice to mirror the impact of sepsis across tissues. Mechanistically, we map the cellular effects of sepsis and cytokines by computing changes in the abundance of 195 cell types across 9 organs, which we validate by whole-mouse spatial profiling. Our work decodes the cytokine cacophony in sepsis into a pairwise cytokine message capturing the gene, cell and tissue responses of the host to the disease.
The invention provides a dental composite material, a multi-layer dental composite material, and a preparation method and application thereof. The preparation method of the dental composite material comprises the following steps: mixing, stirring, shearing and grinding, vacuum defoaming and curing. The multi-layer dental composite is at least 2-layer in structure and contains at least 1 layer of dental composite and/or at least 1 layer of dental polymer. The material can be layered and independent, and has the adjustability of structure and mechanical property, higher fracture resistance, higher elastic modulus and longer fatigue life; the mechanical property is enhanced, and simultaneously the characteristics of portability, attractive appearance, good biocompatibility and the like of the existing dental composite material are kept. The preparation method comprises the following steps: stacking, dropping, calendaring, and curing. The preparation method is simple to operate and low in cost, and can be used for preparing gradient, alternative and monotonous multi-layer dental composite materials which are respectively applied to repairing molar teeth and/or premolar teeth, incisors and/or canine teeth and carious cavities at different positions.
The invention provides a traditional Chinese medicine composition capable of moistening the intestines and relaxing the bowels, belonging to the field of Chinese herbal compounds. The traditional Chinese medicine composition is prepared from the following raw materials by weight: 15 to 20 parts of senna leaf, 10 to 16 parts of fruit of ford manglietia, 6 to 12 parts of Chinese angelica, 6 to 12 parts of cistanche, 6 to 10 parts of licorice root and 6 to 10 parts of honey. The traditional Chinese medicine composition provided by the invention is capable of benefiting lung qi, clearing away deficiency fire and dredging the intestinal tracts. The invention also discloses a preparation method for the traditional Chinese medicine composition. The preparation method comprises the following steps: crushing the Chinese angelica into powder; separately extracting the senna leaf, cistanche, fruit of ford manglietia and licorice root so as to obtain liquid extracts, combining the liquid extracts to obtain a liquid extract mixture and concentrating the liquid extract mixture so as to obtain extract paste; and mixing the powder, the extract paste and the honey so as to obtain the traditional Chinese medicine composition. The method can effectively extract active components in the raw materials.
PURPOSE:To suppress of elution of formaldehyde by adding a reducting substance such as sodium erysorbic acid to a formaldehyde donor such as imidazolidinyl urea in an aqueous system. CONSTITUTION:In an aqueous system, (A) a formaldehyde donor is blended with (B) >=0.1 pt.wt., (preferably >=1 pt.wt.) based on 1 pt.wt. component A of a reducing substance to efficiently suppress elution of formaldehyde without lowering decay preventing power in an antiseptic. 5-Bromo-5-nitro-1,3-dioxane or imidazolidinyl urea is cited as the component A and ascorbic acid or resorcin as the component B. By the above-mentioned method, elution of formaldehyde is suppressed, cosmetic having both antiseptic power and safety or fragrant cosmetic such as toiletry product can be obtained.